There is a need for effective interventions to address the core symptoms and problems associated with autistic spectrum disorder (ASD). Behavior therapy improves communication and behavioral functioning. Additional treatment options include psychopharmacological and biomedical interventions. Although these approaches help children with autistic problems, they may be associated with side effects, risks or require ongoing or long-term treatment. Neurofeedback is a noninvasive approach shown to enhance neuroregulation and metabolic function in ASD. We present a review of the literature on the application of Neurofeedback to the multiple problems associated with ASD. Directions for future research are discussed.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Adams, J., Geis, L., Baral, M., Mitchell, J. I., Hensley, A., Newmark, S., et al. (2008). Results of DMSA treatment study. Presented at the Autism One Conference, Chicago, Illinois.
Aman, M. G., Singh, N. N., & Stewart, A. W. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.
American Academy of Child & Adolescent Psychiatry. (1999, March 3). Secretin in the treatment of autism [Policy statement]. Retrieved August 6, 2007 from http://www.aacap.org/cs/root/policy_statements/secretin_in_the_treatment_of_autism.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, fourth edition-text revision. Washington, DC: American Psychiatric Association.
Amminger, G. P., Berger, G. E., Schafer, M. R., Klier, C., Friedrich, M. H., & Feucht, M. (2007). Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled study. Biological Psychiatry, 61, 551–553.
Anderson, S. R., Avery, D. L., DiPietro, E. K., Edwards, G. L., & Christian, W. P. (1987). Intensive home-based early intervention with autistic children. Education and Treatment of Children, 10, 352–366.
Association for Applied Psychophysiology & Biofeedback. (2006). Efficacy: How we rate the efficacy of our treatments or how to know if our treatments actually work. Retrieved February 22, 2006 from http://www.aapb.org/i4a/pages/index.cfm?pageid=3336.
Attwood, T. (1998). Asperger’s syndrome: A guide for parents and professionals. London, England: Jessica Kingsley Publishers.
Barnard, A. L., Young, A. H., Pearson, A. D. J., Geddes, J., & Obrien, G. (2002). A systematic review of the use of atypical antipsychotics in autism. Journal of Psychopharmacology, 16, 93–102.
Bassett, K., Green, C. J., & Kazanjian, A. (2000). Autism and Lovaas treatment: A systematic review of effectiveness evidence. Vancouver, BC: British Columbia Office of Health Technology Assessment, The University of British Columbia.
Bayley, N. (1993). Bayley scales of infant development (2nd ed.). San Antonio: Psychological Corp.
Bell, J. G., Sargent, J. R., Tocher, D. R., & Dick, J. R. (2000). Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: A characteristic abnormality in neurodevelopmental disorders? Prostaglandins, Leukotienes and Essential Fatty Acids, 63(1–2), 21–25.
Ben-Itzchak, E., & Zachor, D. A. (2007). The effects of intellectual functioning and autism severity on outcome of early intervention for children with autism. Research in Developmental Disabilities, 28, 287–303.
Bernard, S., Enayati, A., Binstock, T., Roger, H., Redwood, L., & McGinnis, W. (2000) Autism: A unique type of mercury poisoning. ARC Research, Available from the Autism Research Institute.
Birnbrauer, J. S., & Leach, D. J. (1993). The Murdoch early intervention program after 2 years. Behavior Change, 10, 63–74.
Blaxill, M. F. (2004). What’s going on? The question of time trends in autism. Public Health Reports, 119, 536–551.
Bradstreet, J., Geier, B. A., Kartzinel, J. J., Adams, J. B., & Geier, M. R. (2003). A case–control study of mercury burden in children with autistic spectrum disorders. Journal of American Physicians and Surgeons, 8(3), 76–79.
Butter, E. M., Mulick, J. A., & Metz, B. (2006). Eight case reports of learning recovery in children with pervasive developmental disorders after early intervention. Behavioral Interventions, 21, 227–243.
Cade, R., Privette, M., Fregley, M., Rowland, N., Sun, Z., Zele, V., et al. (1999). Autism and schizophrenia: Intestinal disorders. Nutritional Neuroscience, 3, 57–72.
Carmen, J. A. (2004). Passive infared hemoencephalography: Four years and 100 migraines. Journal of Neurotherapy, 8(3), 23–51.
Center for Disease Control and Prevention. (2006). How common are autism spectrum disorder (ASD)? Retrieved May 31, 2006 from http://www.cdc.gov/ncbddd/autism/asd_common.htm.
Center for Disease Control and Prevention. (2007). Prevalence of the autism spectrum disorders (ASDs in Multiple Areas of the United States, 2000 and 2002). MMWR, 56 (SS 1–2).
Coben, R. (2006, September). Hemoencephalography for autistic spectrum disorder. Presented at the 14th Annual Conference of the International Society for Neuronal Regulation, Atlanta, Georgia.
Coben, R. (2007, September). Autistic spectrum disorder: A controlled study of EEG coherence training targeting social skill deficits. Presented at the 15th annual conference of the International Society for Neurofeedback and Research, San Diego, California.
Coben, R. (2009). Efficacy of connectivity guided neurofeedback for autistic spectrum disorder: Controlled analysis of 75 cases with a 1 to 2 year follow-up. Journal of Neurotherapy, 13(1), 81.
Coben, R., Hirshberg, L. M., & Chabot, R. (Under Review). EEG discriminant power and subtypes in autistic spectrum disorder. International Journal of Psychophysiology.
Coben, R., & Hudspeth, W. (2006, September). Mu-like rhythms in autistic spectrum disorder: EEG analyses and neurofeedback. Presented at the 14th Annual Conference of the International Society for Neuronal Regulation, Atlanta, Georgia.
Coben, R., & Myers, T. E. (2008). Connectivity theory of autism: Use of connectivity measures in assessing and treating autistic disorders. Journal of Neurotherapy, 12(2–3), 161–179.
Coben, R. & Myers, T. E. (2009). The relative efficacy of connectivity guided and symptom based EEG biofeedback for Autistic disorders. Applied Psychophysiology and Biofeedback. doi:10.1007/s10484-009-9102-5.
Coben, R., & Padolsky, I. (2007). Assessment-guided neurofeedback for autistic spectrum disorder. Journal of Neurotherapy, 11(3), 5–18.
Committee on Children with Disabilities. (2001). Technical report: The pediatrician’s role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics, 107(5), 1–35.
Cook, E. H., Rowlett, R., & Jaselskis, C. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 739–745.
Couper, J. (2004). Who should pay for intensive behavioural intervention in autism? A parent’s view. Journal of Paediatrics and Child Health, 40(9–10), 559–561.
Couturier, J. L., & Nicolson, R. (2002). A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 12, 243–248.
Cowan, J., & Markham, L. (1994, March). EEG biofeedback for the attention problems of autism: A case study. Presented at the 25th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Atlanta, GA.
DeLong, G. R., Ritch, C. R., & Burch, S. (2002). Fluoxetine response in children with autistic spectrum disorders: Correlation with familial major affective disorder and intellectual achievement. Developmental Medicine and Child Neurology, 44, 652–659.
Demos, J. N. (2005). Getting started with neurofeedback. New York: WW Norton & Company.
Deprey, L. J., Brule, N., Widjaja, F., Sepheri, S., Blank, J., Neubrander, J., et al. (2006, October). Double-blind placebo-controlled, cross-over trial of subcutaneous methylcobalamin in children with autism: Preliminary results. Poster presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA.
Deth, R. C. (2004, October) Methylcobalamin for autistic children. Presented at the 34th Annual Meeting of the Society for Neuroscience, San Diego, CA.
Dietrich, K. N., Ware, J. H., Salganik, M., Radcliffe, J., Rogan, W. J., Rhoads, G. G., et al. (2004). Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics, 114, 19–26.
Ducharme, J. M. (2005). Errorless compliance training. In M. Hersen & J. Rosqvist (Eds.), Encyclopedia of behavior modification and cognitive behavior therapy (Vol. 2: Child Clinical Applications). Thousand Oaks, CA: Sage.
Ducharme, J. M., Sanjuan, E., & Drain, T. (2007). Errorless compliance training. Success-focused behavioral treatment of children with Asperger syndrome. Behavior Modification, 31, 329–344.
Egner, T., & Sterman, M. B. (2006). Neurofeedback treatment of epilepsy: From basic rationale to practical application. Expert Review of Neurotherapeutics, 6, 247–257.
Eikeseth, S., Smith, T., Jahr, E., & Eldevik, S. (2002). Intensive behavioral treatment at school for 4–7-year-old children with autism: A 1-year comparison controlled study. Behavior Modification, 26, 49–68.
Eikeseth, S., Smith, T., Jahr, E., & Eldevik, S. (2007). Outcome for children with autism who began intensive behavioral treatment between ages 4 and 7: A comparison controlled study. Behavior Modification, 31, 264–278.
Elder, J. H., Shankar, M., Shuster, J., Theriaque, D., Burns, S., & Sherrill, L. (2006). The gluten-free, casein-free diet in autism: Results of a preliminary double blind clinical trial. Journal of Autism and Developmental Disorders, 36, 413–420.
Esch, B. E., & Carr, J. E. (2004). Secretin as a treatment for autism: A review of the evidence. Journal of Autism and Developmental Disorders, 34, 543–556.
Fenske, E. C., Zalenski, S., Krantz, P. J., & McClannahan, L. E. (1985). Age at intervention and treatment outcome for autistic children in a comprehensive intervention program. Analysis and Intervention in Developmental Disabilities, 5, 49–58.
Fuchs, T., Birbaumer, N., Lutzenberger, W., Gruzelier, J. H., & Kaiser, J. (2003). Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: A comparison with methylphenidate. Applied Psychophysiology and Biofeedback, 28, 1–12.
Geller, D. A., Hoog, S. L., Heiligenstein, J. H., Ricardi, R. K., Tamura, R., Kluszynski, S., et al. (2001). Fluoxetine treatment for obsessive compulsive disorder in children and adolescents: A placebo controlled clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40(7), 773–779.
George, M. S., Costa, D. C., Kouris, K., Ring, H. A., & Ell, P. J. (1992). Cerebral blood flow abnormalities in adults with infantile autism. Journal of Nervous and Mental Disease, 180, 413–417.
Golden, Z. L., Neubauer, R., Golden, C. J., Greene, L., Marsh, J., & Mleko, A. (2002). Improvement in cerebral metabolism in chronic brain injury after hyperbaric oxygen therapy. International Journal of Neuroscience, 112, 119–131.
Green, V. A., Pituch, K. A., Itchon, J., Choi, A., O’Reilly, M., & Sigafoos, J. (2006). Internet survey of treatments used by parents of children with autism. Research in Developmental Disabilities, 27, 70–84.
Hamilton, L. (2000). Facing autism: Giving parents reasons for hope and guidance for help. Colorado Springs, Colorado: Water Brook Press.
Hammond, D. C. (2005). What is neurofeedback? Retrieved July 25, 2006 from http://www.isnr.org/pubarea/whatisnfb.pdf.
Harris, S. L., Handleman, J. S., Gordon, R., Kristoff, B., & Fuentes, F. (1991). Changes in cognitive and language functioning of preschool children with autism. Journal of Autism and Developmental Disorders, 21, 281–290.
Hediger, M. L., England, L. J., Molloy, C. A., Yu, K. F., Manning-Courtney, P., & Mills, J. L. (2008). Reduced bone cortical thickness in boys with autism or autism spectrum disorder. Journal of Autism and Developmental Disorders, 38, 848–856.
Hellings, J. A., Kelley, L. A., Gabrielli, W. F., Kilgore, E., & Shah, P. (1996). Sertraline response in adults with mental retardation and autistic disorder. Journal of Clinical Psychiatry, 57, 333–336.
Herbert, J. D., Sharp, I. R., & Gaudiano, B. A. (2002). Separating fact from fiction in the etiology and treatment of autism. A scientific review of the evidence. The Scientific Review of Mental Health Practice, 1(1). Accessed online at: http://www.srmhp.org/0101/autism.html.
Hill, E. L. (2004). Executive dysfunction in autism. Trends in Cognitive Sciences, 8(1), 26–32.
Hirsch, D. (1999). Secretin in the treatment of autism. The Exceptional Parent, 29, 94.
Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., et al. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30, 582–589.
Holmes, A. (2001). Autism treatments: Chelation of mercury. Retrieved November 2, 2005 from http://www.healing-arts.org/children/holmes.htm .
Horvath, K., Stefanatos, G., Sokolski, K. N., Wachtel, R., Nabors, L., & Tildon, J. T. (1998). Improved social and language skills after secretin administration in patients with autistic spectrum disorders. Journal of the Association for Academic Minority Physicians, 9, 9–15.
Hughes, J. R., & John, E. R. (1999). Conventional and quantitative electroencephalography in psychiatry. Journal of Neuropsychiatry and Clinical Neurosciences, 11, 190–208.
Ibric, V. L., & Hudspeth, W. (2003, February). QEEG and Roshi use in autism post-toxic encephalopathy—a case study. Presented at the 11th Annual Winter Brain Conference, Palm Springs, CA.
Jarusiewicz, B. (2002). Efficacy of neurofeedback for children in the autistic spectrum: A pilot study. Journal of Neurotherapy, 6(4), 39–49.
Jasper, H. (1958). The ten-twenty electrode system of the International Federation. Electroencephalography and Clinical Neurophysiology, 10, 371–375.
Jensen, P. S., et al. (2007). 3-Year follow-up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry, 46(8), 989–1002.
Jesner, O. S., Aref-Adib, M., & Coren, E. (2007). Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews, 1(CD005040). Retrieved July 18, 2008, from Cochrane Database of Systematic Reviews database.
Just, M. A., Cherkassy, V. L., Keller, T. A., & Minshew, N. J. (2004). Cortical activation and synchronization during sentence comprehension in high-functioning autism: Evidence of underconnectivity. Brain, 127, 1811–1821.
Kirby, D. (2005). Evidence of harm: Mercury in vaccines and the autism epidemic: A medical controversy. New York: St. Martin’s Press.
Knivsberg, A. M., Reichelt, K. L., Hoien, T., & Nodland, M. (2002). A randomized, controlled study of dietary intervention in autistic syndromes. Nutritional Neuroscience, 5, 251–261.
Kouijzer, M. E. J., de Moor, J. M. H., Gerrits, B. J. L., Buitelaar, J. K., & van Schie, H. T. (2009a). Long-term effects of neurofeedback treatment in autism. Research in Autism Spectrum Disorders, 3(2), 496–501.
Kouijzer, M. E. J., de Moor, J. M. H., Gerrits, B. J. L., Congedo, M., & van Schie, H. T. (2009b). Neurofeedback improves executive functioning in children with autism spectrum disorders. Research in Autism Spectrum Disorders, 3(1), 145–162.
Laibow, R. (1999). Medical applications of neurofeedback. In J. R. Evans & A. Abarbanel (Eds.), Introduction to quantitative EEG and neurofeedback (pp. 83–102). San Diego, CA: Academic Press.
LaVaque, T. J., Hammond, D. C., Trudeau, D., Monastra, V., Perry, J., Lehrer, P., et al. (2002). Template for developing guidelines for the evaluation of the clinical efficacy of psychophysiological evaluations. Applied Psychophysiology and Biofeedback, 27(4), 273–281.
Limsila, P., Toomim, H., Kijvithee, J., Bunthong, W., Pookjinda, J., & Utairatanakit, D. (2004). Hemoencephalography (HEG): An additional treatment for autism. Retrieved August 7, 2006 from http://www.biocompresearch.org/Thai_autism_study.htm.
Linden, M. (2004, August). Case studies of QEEG mapping and neurofeedback with autism. Presented at the 12th Annual Conference of the International Society for Neuronal Regulation, Fort Lauderdale, FL.
Linden, M., Habib, T., & Radojevic, V. (1996). A controlled study of the effects of EEG biofeedback on cognition and behavior of children with attention deficit disorder and learning disabilities. Biofeedback and Self-Regulation, 21, 35–50.
Lord, C., Rutter, M., DiLavore, P. C., & Risi, S. (1999). Autism diagnostic observation schedule-WPS (ADOS-WPS). Los Angeles, CA: Western Psychological Services.
Lovaas, O. I. (1987). Behavioral treatment and normal educational and intellectual functioning in young autistic children. Journal of Consulting and Clinical Psychology, 55, 3–9.
Lovaas, O. I., Koegel, R., Simmons, J. Q., & Long, J. S. (1973). Some generalization and follow-up measures on autistic children in behavior therapy. Journal of Applied Behavior Analysis, 6(1), 131–165.
Lubar, J. F. (1995). Neurofeedback for the management of attention-deficit/hyperactivity disorders. In M. S. Schwartz (Ed.), Biofeedback: A practitioner’s guide (3rd ed., pp. 493–522). New York: Guilford.
Lubar, J. F. (1997). Neurobiological foundation for neurofeedback treatment of attention deficit hyperactivity disorder (ADD/HD). Biofeedback, 25(10), 4–23.
Lubar, J. F., & Bahler, W. W. (1976). Behavioral management of epileptic seizures following EEG biofeedback training of the sensorimotor rhythm. Biofeedback and Self-Regulation, 7, 77–104.
Lubar, J. F., Swartwood, M. O., Swartwood, J. N., & O’Donnell, P. H. (1995). Evaluation of the effectiveness of EEG training for ADHD in a clinical setting as measured by TOVA scores, behavioral ratings, and WISC-R performance. Biofeedback and Self-Regulation, 20, 83–99.
Madsen, K. M., Lauritsen, M. B., Pedersen, C. B., Thorsen, P., Plesner, A., Andersen, P. H., et al. (2003). Thimerosal and the occurrence of autism: Negative ecological evidence from Danish population-based data. Pediatrics, 112, 604–606.
Martin, A., Koenig, K., Anderson, G., & Scahill, L. (2003). Low dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders, 33(1), 77–85.
Martin, A., Scahill, L., Klin, A., & Volkmar, F. R. (1999). Higher functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 923–931.
McAlonan, G. M., Cheung, V., Cheung, C., Suckling, J., Lam, G. Y., Tai, K. S., et al. (2004). Mapping the brain in autism: A voxel-based MRI study of volumetric differences and intercorrelations in autism. Brain, 128(Pt 2), 268–276.
McCandless, J. (2005). Children with starving brains: A medical treatment guide for autism spectrum disorder. Putney, VT: Bramble Books.
McDougle, C. J., Brodkin, E. S., Naylor, S. T., Carlson, D. C., Cohen, D. J., & Price, L. H. (1998). Sertraline in adults with pervasive developmental disorders: A prospective, open-label investigation. Journal of Clinical Psychopharmacology, 18, 62–66.
McDougle, C. J., Kresch, L. E., Goodman, W. K., Naylor, S. T., Volkmar, F. R., Cohen, D. J., et al. (1995). A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive–compulsive disorder. American Journal of Psychiatry, 152, 772–777.
McDougle, C. J., Kresch, L. E., & Posey, D. J. (2000). Repetitive thoughts and behavior in pervasive developmental disorders: Treatment with serotonin reuptake inhibitors. Journal of Autism and Developmental Disorders, 30, 427–435.
McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996). A double-blind, placebo controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001–1008.
McEachin, J. J., Smith, T., & Lovaas, O. I. (1993). Long-term outcome for children with autism who received early intensive behavioral treatment. American Journal of Mental Retardation, 97, 359–372.
Monastra, V. J., Lynn, S., Linden, M., Lubar, J. F., Gruzelier, J., & LaVaque, T. J. (2005). Electroencephalographic biofeedback in the treatment of attention-deficit/hyperactivity disorder. Applied Psychophysiology and Biofeedback, 30, 95–114.
Monastra, V. J., Monastra, D. M., & George, S. (2002). The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. Applied Psychophysiology and Biofeedback, 27, 231–249.
Montgomery, D., Goldberg, J., Amar, M., Lacroix, V., Lecomte, J., Venasse, M., et al. (1999). Effects of hyperbaric oxygen therapy on children with spastic diplegic cerebral palsy: A pilot project. Undersea and Hyperbaric Medicine, 26, 235–242.
Mountz, J. M., Tolbert, L. C., Lill, D. W., Katholi, C. R., & Liu, H. G. (1995). Functional deficits in autistic disorder: Characterization by technetium-99 m-HMPAO and SPECT. Journal of Nuclear Medicine, 36, 1156–1162.
Mundy, P. (1993). Normal versus high-functioning status in children with autism. American Journal on Mental Retardation, 97, 381–384.
Nakano, K., Noda, N., Tachikawa, E., Urano, M., Takazawa, M., Nakayama, T., et al. (2005). A preliminary study of methylcobalamin therapy in autism. Journal of Tokyo Women’s Medical Unversity, 75(3/4), 64–69.
Namerow, L. B., Thomas, P., Bostic, J. Q., Prince, J., & Monuteaux, M. C. (2003). Use of citalopram in pervasive developmental disorders. Journal of Developmental and Behavioral Pediatrics, 24(2), 104–108.
National Institute of Child Health and Human Development. (1999, December 8). [National Institutes of Health News Alert]. Study shows secretin fails to benefit children with autism. Retrieved August 6, 2007, from http://www.nichd.nih.gov/news/releases/secretin.cfm.
National Institute of Mental Health. (2006). Autism spectrum disorders (pervasive developmental disorders). Retrieved June 7, 2006 from http://www.nimh.nih.gov/publicat/autism.cfm.
Neubrander, J. A. (2005, May). Methyl-B12: Making it work for you! Presented at the Autism One Conference, Chicago, IL.
Nighoghossian, N., Trouillas, P., Adeleine, P., & Salord, F. (1995). Hyperbaric oxygen in the treatment of acute ischemic stroke. Stroke, 26, 1369–1372.
Oberman, L. M., Hubbard, E. M., McCleery, J. P., Altschuler, E. L., Ramachandran, V. S., & Pineda, J. A. (2005). EEG evidence for mirror neuron dysfunction in autism spectrum disorders. Cognitive Brain Research, 24, 190–198.
Ohnishi, T., Matsuda, H., Hashimoto, T., Kunihiro, T., Nishikawa, M., Uema, T., et al. (2000). Abnormal regional cerebral blood flow in childhood autism. Brain, 123, 1838–1844.
Othmer, S. (1997). Assessment. EEG spectrum biofeedback training manual. Encino, CA: EEG Spectrum, Inc.
Owley, T., Walton, L., Salt, J., Guter, S. J., Winnega, M., Leventhal, B. L., et al. (2005). An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 343–348.
Ozonoff, S., & Cathcart, K. (1998). Effectiveness of a home program intervention for young children with autism. Journal of Autism and Developmental Disorders, 28, 25–32.
Paolo, M., Viti, M. G., Montouri, M., LaVecchia, A., Cipolletta, E., Calvani, L., et al. (1998). The gluten-free diet: A nutritional risk factor for adolescents with celiac disease? Journal of Pediatric Gastroenterology and Nutrition, 27, 519–523.
Pelphrey, K., Adolphs, R., & Morris, J. P. (2004). Neuroanatomical substrates of social cognition dysfunction in autism. Mental Retardation and Developmental Disabilities Research Reviews, 10, 259–271.
Pineda, J. A., et al. (2008). Positive behavioral and electrophysiological changes following neurofeedback training in children with autism. Research in Autism Spectrum Disorders, 2(3), 557–581.
Posey, D. J., Litwiller, M., Koburn, A., & McDougle, C. J. (1999). Paroxetine in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38(2), 111–112.
Rangaswamy, M., Porjesz, B., Chorlian, D. B., Wang, K., Jones, K. A., Bauer, L. O., et al. (2002). Beta power in the EEG of alcoholics. Biological Psychiatry, 52, 831–842.
Reichelt, K. (2001, October). Opioid peptides. Paper presented at the Defeat Autism Now Conference, San Diego, California.
Reichelt, K., & Knivsberg, A. M. (2003, October). Why use the gluten-free and casein-free diet in autism and what the results have shown so far: Peptides and autism. Paper presented at the Defeat Autism Now Conference, Portland, Oregon.
Research Units on Pediatric Psychopharmacology Autism Network. (2005a). Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry, 162, 1361–1369.
Research Units on Pediatric Psychopharmacology Autism Network. (2005b). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274.
Rimland, B., & Edelson, S. M. (2000). Autism treatment evaluation checklist (ATEC). Retrieved October 5, 2005 from http://autismeval.com/ari-atec/report1.html.
Rippon, G., Brock, J., Brown, C., & Boucher, J. (2007). Disordered connectivity in the autistic brain: Challenges for the ‘new psychophysiology’. International Journal of Psychophysiology, 63(2), 164–172.
Roberts, W., Weaver, L., Brian, J., Bryson, S., Emelianova, S., Griffiths, A. M., et al. (2001). Repeated doses of porcine secretin in the treatment of autism: A randomized, placebo-controlled trial. Pediatrics, 107(5), 71–80.
Ross, J., & Caunt, J. (2003, September). A comparison of QEEG characteristics in pediatric Asperger’s syndrome and attention deficit disorder. Paper presented at the 11th Annual Conference of the International Society of Neuronal Regulation, Houston, TX.
Rossignol, D. A., & Rossignol, L. W. (2006). Hyperbaric oxygen therapy may improve symptoms in autistic children. Medical Hypotheses, 67, 216–228.
Rossignol, D. A., Rossignol, L. W., James, S. J., Melnyk, S., & Mumper, E. (2007). The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptom sin children with autism: An open-label pilot study. BMC Pediatrics, 7, 36–49.
Rutter, M., LeCouteur, A., & Lord, C. (2003). Autism diagnostic interview-revised. Los Angeles, CA: Western Psychological Services.
Sallows, G. O., & Graupner, T. D. (2005). Behavioral treatment for children with autism: Four-year outcome and predictors. American Journal of Mental Retardation, 110(6), 417–438.
Sandler, A. D., Sutton, K. A., DeWeese, J., Girardi, M. A., Sheppard, V., & Bodfish, J. W. (1999). Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. New England Journal of Medicine, 341, 1801–1806.
Santangelo, S. L., & Tsatsanis, K. (2005). What is known about autism: Genes, brain, and behavior. American Journal of Pharmacogenomics, 5(2), 71–92.
Schmitz, N., Rubia, K., Daly, E., Smith, A., Williams, S., & Murphy, D. G. (2006). Neural correlates of executive function in autistic spectrum disorders. Biological Psychiatry, 59(1), 7–16.
Schopler, E., & Reichler, R. J. (1971). Parents as cotherapists in the treatment of psychotic children. Journal of Autism and Childhood Schizophrenia, 1, 87–102.
Schopler, E., Reichler, R. J., Bashford, A., Lansing, M. D., & Marcus, L. M. (1990). Individualized assessment and treatment for autistic and developmentally disables children (vol. 1): Psychoeducational profile revised. Austin, TX: PRO-ED.
Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980). Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders, 10(1), 91–103.
Schopler, E., Short, A., & Mesibov, G. (1989). Relation of behavioral treatment to “normal functioning”: Comments on Lovaas. Journal of Consulting and Clinical Psychology, 57, 162–164.
Scolnick, B. (2005). Effects of electroencephalogram biofeedback with Asperger’s syndrome. International Journal of Rehabilitation Research, 28(2), 159–163.
Sheinkopf, S., & Siegel, B. (1998). Home-based behavioral treatment of young children with autism. Journal of Autism and Developmental Disorders, 28, 15–23.
Sichel, A. G., Fehmi, L. G., & Goldstein, D. M. (1995). Positive outcome with neurofeedback treatment in a case of mild autism. Journal of Neurotherapy, 1(1), 60–64.
Sicile-Kira, C. (2004). Autism spectrum disorders: The complete guide to understanding autism, Asperger’s syndrome, pervasive developmental disorder, and ASDs. New York: The Berkley Publishing Group.
Siegel, B. (1996). The world of the autistic child: Understanding and treating autistic spectrum disorders. New York: Oxford University Press.
Sinha, Y., Silove, N., & Williams, K. (2006). Chelation therapy and autism. British Medical Journal, 333(7571), 756.
Smith, T., Groen, A. D., & Wynn, J. W. (2000). Randomized trial of intensive early intervention for children with pervasive developmental disorder. American Journal on Mental Retardation, 105, 269–285.
Snead, R. W., Boon, F., & Presberg, J. (1994). Paroxetine for self-injurious behavior. Journal of the American Academy of Child and Adolescent Psychiatry, 33(6), 909–910.
Starkstein, S. E., Vazquez, S., Vrancic, D., Nanclares, V., Manes, F., Piven, J., et al. (2000). SPECT findings in mentally retarded autistic individuals. Journal of Neuropsychiatry and Clinical Neurosciences, 12, 370–375.
Steingard, R. J., Zimnitzky, B., DeMaso, D. R., Bauman, M. L., & Bucci, J. P. (1997). Sertraline treatment of transition associated anxiety and agitation in children with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 7(1), 9–15.
Sterman, M. B., & Friar, L. (1972). Suppression of seizures in an epileptic following sensorimotor EEG feedback training. Journal of Electroencephalography and Clinical Neurophysiology, 33, 89–95.
Stigler, K. A., Posey, D. J., & McDougle, C. J. (2004). Case report: Aripiprazole for maladaptive behavior in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14(3), 455–463.
Stoller, K. P. (2005). Quantification of neurocognitive changes before, during, and after hyperbaric oxygen therapy in a case of fetal alcohol syndrome. Pediatrics, 116(4), e586–e591.
Stratton, K., Gable, G., & McCormick, M. C. (Eds.). (2001). Immunization safety review: Thimerosal containing vaccines and neurodevelopmental disorders. Washington, DC: National Academy Press.
Tansey, M. A. (1993). Ten-year stability study of EEG biofeedback results for a hyperactive boy who failed a fourth grade perceptually impaired class. Biofeedback and Self-Regulation, 18(1), 33–44.
Thompson, L., & Thompson, M. (1995, May). Autism/Asperger’s/obnoxious child, 3 case histories: How we get positive results with complex ADD clients. Paper presented at the Annual Conference of the Society for Neuronal Regulation, Scottsdale, AZ.
Thompson, L., & Thompson, M. (2003a). Neurofeedback treatment for autistic spectrum disorders: Review of 60 cases-principles and outcome. Citation paper presented at the 34th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Jacksonville, FL.
Thompson, M., & Thompson, L. (2003b). The neurofeedback book: An introduction to basic concepts in applied psychophysiology. Wheat Ridge, CO: Association for Applied Psychophysiology and Biofeedback.
Thompson, L., & Thompson, M. (2007, February). Autistic spectrum disorders, especially Asperger’s syndrome. Oral paper presented at the 38th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Monterey, CA.
Toomim, H., Mize, W., Kwong, P. C., Toomim, M., Marsh, R., Koslowski, G. P., et al. (2004). Intentional increase of cerebral blood oxygenation (HEG): An efficient brain exercise therapy. Journal of Neurotherapy, 8(3), 5–21.
Troost, P. W., Lahuis, B. E., Steenhuis, M. P., Ketelaars, C. E., Buitelaar, J. K., van Engeland, H., et al. (2005). Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. Journal of the American Academy of Child & Adolescent Psychiatry, 44(11), 1137–1144.
Vancassel, S., Durand, G., Barthelemy, C., Lejeune, B., Martineau, J., Guilloteau, D., et al. (2001). Plasma fatty acid levels in autistic children. Prostaglandins, Leukotrienes and Essential Fatty Acids, 65(1), 1–7.
Verstraeten, T., Davis, R. L., DeStefano, F., Lieu, T. A., Rhodes, P. H., Black, S. B., et al. (2004). Safety of thimerosal-containing vaccines: A two-phased study of computerized health maintenance organization databases. Pediatrics, 112, 1039–1048.
Wainright, P. E. (2002). Dietary essential fatty acids and brain function: A developmental perspective on mechanisms. The Proceedings of the Nutrition Society, 61, 61–69.
Wechsler, D. (1989). Wechsler preschool and primary scale of intelligence-revised. San Antonio, TX: Psychological Corp.
Welchew, D. E., Ashwin, C., Berkouk, K., Salvador, R., Suckling, J., Baron-Cohen, S., et al. (2005). Functional disconnectivity of the medial temporal lobe in Asperger’s syndrome. Biological Psychiatry, 57, 991–998.
Yucha, C., & Montgomery, D. (2008). Evidence-based practice in biofeedback and neurofeedback. Wheat Ridge, CO: Association for Applied Psychophysiology and Biofeedback.
Zilbovicius, M., Boddaert, N., Belin, P., Poline, J. B., Remy, P., Mangin, J. F., et al. (2000). Temporal lobe dysfunction in childhood autism: A PET study. American Journal of Psychiatry, 157, 1988–1993.
Zuddas, A., Di Martino, A., Muglia, P., & Cichetti, C. (2000). Long-term risperidone for pervasive developmental disorder: Efficacy, tolerability, and discontinuation. Journal of Child and Adolescent Psychopharmacology, 10, 79–90.
About this article
Cite this article
Coben, R., Linden, M. & Myers, T.E. Neurofeedback for Autistic Spectrum Disorder: A Review of the Literature. Appl Psychophysiol Biofeedback 35, 83 (2010). https://doi.org/10.1007/s10484-009-9117-y
- Autistic spectrum disorder